{
    "organizations": [],
    "uuid": "3e9ed4c1afef457b37ab055d293ba313d8efb836",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dar-bioscience-announces-effective/brief-dar-bioscience-announces-effective-license-collaboration-deal-for-topical-sildenafil-idUSFWN1Q517Q",
    "ord_in_thread": 0,
    "title": "BRIEF-Daré Bioscience Announces Effective License, Collaboration Deal For Topical Sildenafil",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 15 (Reuters) - Dare Bioscience Inc:\n* DARÉ BIOSCIENCE, INC. ANNOUNCES EFFECTIVE LICENSE AND COLLABORATION AGREEMENT FOR TOPICAL SILDENAFIL FOR FEMALE SEXUAL AROUSAL DISORDER\n* DARE BIOSCIENCE SAYS MET FUNDING REQUIREMENT FOR OBTAINING EXCLUSIVE WORLDWIDE LICENSE TO ADVANCE SST-6007 (5% TOPICAL SILDENAFIL CITRATE CREAM)\n* DARE BIOSCIENCE - PLANS TO PURSUE 505(B)(2) REGULATORY PATHWAY FOR SST-6007 IN U.S.\n* DARE BIOSCIENCE - FUNDS WILL BE USED TO ADVANCE SST-6007 (5% TOPICAL SILDENAFIL CITRATE CREAM) THROUGH NEXT PHASE OF CLINICAL DEVELOPMENT\n* DARE BIOSCIENCE INC - ANTICIPATES COMMENCING A PHASE 2B CLINICAL TRIAL FOR SST-6007 IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-16T00:13:00.000+02:00",
    "crawled": "2018-02-16T17:15:26.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "dare",
        "bioscience",
        "inc",
        "daré",
        "bioscience",
        "announces",
        "effective",
        "license",
        "collaboration",
        "agreement",
        "topical",
        "sildenafil",
        "female",
        "sexual",
        "arousal",
        "disorder",
        "dare",
        "bioscience",
        "say",
        "met",
        "funding",
        "requirement",
        "obtaining",
        "exclusive",
        "worldwide",
        "license",
        "advance",
        "topical",
        "sildenafil",
        "citrate",
        "cream",
        "dare",
        "bioscience",
        "plan",
        "pursue",
        "b",
        "regulatory",
        "pathway",
        "dare",
        "bioscience",
        "fund",
        "used",
        "advance",
        "topical",
        "sildenafil",
        "citrate",
        "cream",
        "next",
        "phase",
        "clinical",
        "development",
        "dare",
        "bioscience",
        "inc",
        "anticipates",
        "commencing",
        "phase",
        "2b",
        "clinical",
        "trial",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}